Skip to main content

Table 1 Correlation of S100 with different pathological grade status of ovarian cancer patients

From: Prognostic values of S100 family members in ovarian cancer patients

S100 family Affymetrix IDs No. of patients (n) Grade HR 95%CI P value
low exp high exp
S100A1 205334_at 23 33 I 0.59 0.23–1.49 0.25
223 101 II 0.91 0.66–1.25 0.54
542 473 III 0.89 0.75–1.05 0.16
8 12 IV 0.07 0.01–0.34 3.20E-05
S100A2 204268_at 39 17 I 0.14 0.02–1.04 0.025
80 244 II 1.3 0.91–1.86 0.15
584 431 III 1.27 1.07–1.5 0.0051
5 15 IV 1.83 0.59–5.69 0.29
S100A3 206027_at 23 33 I 2.22 0.73–6.77 0.15
166 158 II 1.26 0.93–1.71 0.13
319 696 III 0.78 0.65–0.93 0.0056
9 11 IV 0.36 0.12–1.04 0.049
S100A4 203186_s_at 41 15 I 0.63 0.21–1.93 0.41
233 91 II 1.46 1.06–2.03 0.021
441 574 III 1.09 0.92–1.29 0.3
11 9 IV 0.21 0.06–0.66 0.0036
S100A5 207763_at 39 17 I 0.53 0.17–1.62 0.26
155 169 II 1.32 0.98–1.79 0.071
255 760 III 0.79 0.66–0.95 0.011
12 8 IV 0.44 0.15–1.3 0.13
S100A6 217728_at 13 43 I 0.41 0.14–1.19 0.092
227 97 II 1.4 1.02–1.93 0.038
699 316 III 0.83 0.7–1 0.051
10 10 IV 0.29 0.1–0.88 0.021
S100A7 205916_at 27 14 I 4.36 1.42–13.42 0.0051
227 97 II 0.84 0.6–1.17 0.3
564 451 III 0.9 0.76–1.06 0.2
6 14 IV 0.47 0.17–1.31 0.14
S100A7A 232170_at 32 24 I 0.52 0.19–1.39 0.18
72 90 II 1.39 0.9–2.17 0.14
177 215 III 0.81 0.63–1.04 0.093
   IV    
S100A8 202917_s_at 41 15 I 0.46 0.13–1.61 0.22
90 234 II 0.77 0.56–1.06 0.11
318 697 III 0.75 0.63–0.89 0.0012
4 16 IV 0.55 0.17–1.73 0.3
S100A9 203535_at 37 19 I 1.66 0.62–4.48 0.31
104 220 II 0.75 0.55–1.03 0.071
427 588 III 0.85 0.72–1 0.052
14 6 IV 2.18 0.74–6.39 0.15
S100A10 200872_at 23 33 I 0.56 0.21–1.48 0.24
122 202 II 1.34 0.97–1.84 0.072
735 280 III 1.38 1.15–1.65 0.00058
12 8 IV 0.56 0.21–1.48 0.24
S100A11 200660_at 14 42 I 0.62 0.24–1.62 0.32
232 92 II 0.75 0.53–1.06 0.099
591 424 III 1.1 0.93–1.3 0.26
5 15 IV 1.58 0.51–4.89 0.42
S100A12 205863_at 35 21 I 1.91 0.73–4.99 0.18
80 244 II 0.56 0.41–0.78 0.00043
584 431 III 0.9 0.76–1.06 0.21
12 8 IV 1.66 0.63–4.4 0.3
S100A13 202598_at 35 21 I 1.6 0.59–4.33 0.35
209 115 II 0.73 0.53–1.01 0.058
274 741 III 0.87 0.72–1.04 0.12
9 11 IV 0.04 0–0.34 6.00E-05
S100A14 218677_at 27 29 I 1.86 0.65–5.32 0.24
139 185 II 0.78 0.58–1.06 0.11
601 414 III 0.87 0.74–1.03 0.11
6 14 IV 0.34 0.12–0.97 0.035
S100A16 227998_at 11 30 I 0.53 0.17–1.63 0.26
40 122 II 1.75 1.02–3.01 0.04
263 129 III 1.29 1–1.67 0.05
   IV    
S100B 209686_at 39 17 I 2.05 0.76–5.5 0.15
242 82 II 1.41 1.02–1.94 0.036
313 702 III 0.83 0.7–0.99 0.037
4 16 IV 0.46 0.14–1.47 0.18
S100G 207885_at 13 43 I 0.27 0.09–0.87 0.019
91 233 II 0.77 0.55–1.08 0.13
358 657 III 0.87 0.73–1.03 0.11
6 14 IV 0.71 0.26–1.94 0.51
S100P 204351_at 13 43 I 0.65 0.25–1.72 0.38
108 216 II 0.87 0.64–1.2 0.4
408 607 III 1.25 1.06–1.48 0.0096
14 6 IV 0.08 0.01–0.62 0.0023
S100Z 1554876_a_at 9 32 I 301,908,007.1 0-Inf 0.031
107 55 II 0.6 0.37–0.96 0.032
233 159 III 1.29 1–1.66 0.051
   IV    
  1. Notes: exp expression, OS overall survival, HR hazard ratio, CI confidence interval